Faeth Therapeutics
FTH
37 hedge funds and large institutions have $19.7M invested in Faeth Therapeutics in 2021 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 15 increasing their positions, 8 reducing their positions, and 13 closing their positions.
88% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 8
0.41% less ownership
Funds ownership: 11.54% → 11.13% (-0.41%)
12% less funds holding
Funds holding: 42 → 37 (-5)
31% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 13
35% less capital inflows, than outflows
Capital inflows: $3.39M | Capital outflows: $5.23M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.51M |
| 2 |
State Street
Boston,
Massachusetts
|
+$316K |
| 3 |
Morgan Stanley
New York
|
+$250K |
| 4 |
Two Sigma Investments
New York
|
+$215K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$160K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$1.3M |
| 2 |
Millennium Management
New York
|
-$1.28M |
| 3 |
Moore Capital Management
New York
|
-$519K |
| 4 |
ALPS Advisors
Denver,
Colorado
|
-$394K |
| 5 |
Mission Creek Capital Partners
San Francisco,
California
|
-$345K |
FTH Hedge Fund Activity: Q4 2021 in Review
37 of the 6,522 institutional investors tracked by Wall St. Rank reported a position in Faeth Therapeutics (FTH) for Q4 2021, worth a combined $19.7M — down 47% from $37.1M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of FTH and 9 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 15 added.
The largest buyer was BlackRock, adding an estimated $1.51M. The largest seller was Citadel Advisors, exiting entirely with an estimated $1.3M sold.
- 37 institutional investors held Faeth Therapeutics (FTH) as of Q4 2021, down from 42 in Q3 2021.
- Funds reported $19.7M of Faeth Therapeutics stock for Q4 2021, down 47% quarter-over-quarter.
- 9 funds opened new Faeth Therapeutics positions in Q4 2021 and 13 closed out, a net change of -4 holders.
- The largest Faeth Therapeutics buyer in Q4 2021 was BlackRock, an estimated $1.51M added.
- The largest Faeth Therapeutics seller in Q4 2021 was Citadel Advisors, an estimated $1.3M sold.
Based on aggregated 13F filings for Q4 2021.